修订版Nellix使用说明对腹主动脉瘤腔内封闭术后结局的影响
单中心回顾性研究对100例按2013版Nellix使用说明行标准双侧EVAS的患者重新应用2016修订版使用说明,解剖适用率由75%降至34%;两组总生存率和免于再干预率无显著差异,提示新使用说明效果有限。
要点
- 2016版使用说明使解剖适用率从2013版的75%降至34%。
- 不符合2016版使用说明的最主要形态学特征是血栓比率>1.4。
- 两组生存率和免于再干预率无显著差异,提示新使用说明效果有限。
核心结论
- 2016版使用说明使解剖适用率从2013版的75%降至34%。
- 两组生存率和再干预率无显著组间差异,提示新使用说明效果有限。
研究设计与样本
- 单中心研究纳入2013年7月至2015年8月择期行标准双侧EVAS的100例连续患者(平均年龄72±8岁,范围46-91岁;89例男性),随访至2017年12月。
- 按2013版使用说明原分类为内75例、外25例,按2016修订版重新分类为内34例、外66例。
- 采用逐步后退逻辑回归分析评估特定解剖特征对內漏和/或移位的预后价值。
主要发现
- 不符合2016版使用说明的最重要单一形态学特征为血栓比率>1.4(41例重新分类患者中36例)。
- 总体技术成功率为98%(2016版使用说明内100% vs 外97%,p=0.323),30天死亡率为3%(内0% vs 外5%,p=0.251)。
- 中位随访31个月(范围0-53)期间,总体死亡率为21%(内15% vs 外24%,p=0.469);动脉瘤相关死亡率为8%(内3% vs 外11%,p=0.533)。
- 26例发生內漏(内6例 vs 外20例,p=0.172),23例发生移位(内4例 vs 外19例,p=0.088);26例接受再干预(内7例 vs 外19例,p=0.376)。
- 近端瘤颈长度<10 mm和瘤颈角度>60°均为发生內漏和/或移位的阳性预测因素;2016版使用说明内 vs 外组在免于移位(p=0.026)和免于內漏和/或移位复合终点(p=0.021)上差异显著,但生存率(p=0.201)和免于再干预率(p=0.505)无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the impact of the revised Nellix instructions for use (IFU) from 2016 on clinical outcomes and anatomic applicability by retrospectively applying them to a cohort treated with endovascular aneurysm sealing according to the original IFU 2013. METHODS: A single-center study was conducted of 100 consecutive patients (mean age 72±8 years, range 46-91; 89 men) treated electively with standard bilateral EVAS from July 2013 to August 2015 and followed through December 2017. Procedures previously classified within and outside the original IFU from 2013 (75 and 25, respectively) were reclassified according to the revised IFU 2016 (34 and 66, respectively). Stepwise backward logistic regression analysis was performed to evaluate the prognostic value of specific anatomic features for the development of endoleak and/or migration. RESULTS: The single most important morphologic feature disqualifying patients from being within IFU 2016 was a thrombus ratio >1.4 (36 of 41 reclassified patients). Overall technical success was 98% (100% within vs 97% outside IFU 2016, p=0.323) and 30-day mortality was 3% (0% within vs 5% outside IFU 2016, p=0.251). During a median follow-up of 31 months (range 0-53), overall mortality was 21% (15% within vs 24% outside IFU 2016, p=0.469); aneurysm-related mortality was 8% (3% within vs 11% outside IFU 2016, p=0.533). Twenty-six patients developed an endoleak (6 within vs 20 outside IFU 2016, p=0.172) and 23 had migration (4 within vs 19 outside IFU 2016, p=0.088). Both proximal neck length <10 mm and neck angulation >60° were positive predictors for the development of endoleak and/or migration. A reintervention was performed in 26 patients (7 within vs 19 outside IFU 2016, p=0.376). While a significant difference was found between the within vs outside IFU 2016 groups with regard to freedom from migration (p=0.026) and the composite freedom from endoleak and/or migration (p=0.021), there were no significant differences in survival (p=0.201) or freedom from reintervention (p=0.505), suggesting a limited effectiveness of the new IFU 2016. CONCLUSION: The IFU 2016 reduced the anatomic applicability to 34% from 75% for the original IFU 2013. The lack of significant intergroup differences in terms of survival and reinterventions suggests a limited effectiveness of the new IFU 2016.
引用
- Zerwes S, Bruijnen HK, Gosslau Y, et al. Influence of the Revised Nellix Instructions for Use on Outcomes After Endovascular Aneurysm Sealing. J Endovasc Ther. 2018. PMID: 29896999. doi:10.1177/1526602818781353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。